COPENHAGEN (Reuters) - Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.
“People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That’s why we are very excited about the results from LEADER (trial), which showed that Victoza ... also reduces their risk of major adverse cardiovascular events,” Novo’s Chief Science Officer Mads Krogsgaard Thomsen said.
Novo Nordisk’s shares jumped as much as 7 percent in the minutes after the announcement.
Reporting by Sabina Zawadzki; Editing by Elaine Hardcastle
Our Standards: The Thomson Reuters Trust Principles.